Biotechnology
-
Politics & Policy
AI’s Dual Edge: Financial Markets Grapple with Biosecurity Threats
The emergence of artificial intelligence with the capacity to generate synthetic biological agents introduces profound and complex challenges to global…
Read More » -
Investing & Wealth
AstraZeneca and Bristol Myers Squibb: A $400 Billion Megadeal Looming?
Reports indicate discussions between pharmaceutical giants AstraZeneca and Bristol Myers Squibb regarding a staggering pharmaceutical megadeal valued at $400 billion.…
Read More » -
Investing & Wealth
Can $750 Million Reshape US Drug Manufacturing Resilience?
Eli Lilly and National Resilience are set to infuse $750 million into expanding **US drug manufacturing** capabilities, a strategic move…
Read More » -
Investing & Wealth
AstraZeneca Trial Failure: A Rare Test for Pharma Giant’s Resilience
The recent AstraZeneca trial failure has ignited significant discussion across the pharmaceutical industry, challenging investor confidence in a company long…
Read More »
